SCHEMBL3017097

SCHEMBL3017097

CCOc1ccc(-c2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.56
ALDH1A1 P00352 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 8/20 0.53
MAPK1 P28482 5/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 8/20 0.52
TSHR P16473 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
POLB P06746 3/20 0.51
USP2 O75604 2/20 0.51
HSD17B10 Q99714 2/20 0.51
RECQL P46063 1/20 0.51
TDP1 Q9NUW8 1/20 0.46
HTT P42858 2/20 0.46
NOD2 Q9HC29 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001214 0.92 LMNA (0.53) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3020445 0.91 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3014467 0.90 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3013891 0.89 POLB (0.62) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3018460 0.89 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3014263 0.87 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3016516 0.87 MAPT (0.53) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3006146 0.87 MAPT (0.53) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3014364 0.87 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1
SCHEMBL3019989 0.86 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.